---
layout: post
title: "Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry; Availability; Reopening of the Comment Period"
date: 2026-02-05 19:08:49 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-05323
original_published: 2021-03-16 00:00:00 +0000
significance: 8.00
---

# Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry; Availability; Reopening of the Comment Period

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 16, 2021 00:00 UTC
**Document Number:** 2021-05323

## Summary

The Food and Drug Administration (FDA or Agency) is reopening the comment period for the notice entitled "Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry; Availability" that appeared in the Federal Register of December 9, 2020. The Agency is taking this action to allow interested persons additional time to submit comments.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/03/16/2021-05323/best-practices-in-developing-proprietary-names-for-human-nonprescription-drug-products-draft)
- API: https://www.federalregister.gov/api/v1/documents/2021-05323

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
